South Korea Chemiluminescence Immunoassay Market (2026-2031)
The South Korea Chemiluminescence Immunoassay Market was valued at $155.7 Million in 2026 and projected to reach to $228.8 Million by 2031, representing a compound annual growth rate of 8.0%. South Korea's chemiluminescence immunoassay market is experiencing robust growth driven by the country's commitment to healthcare innovation and diagnostic excellence.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
South Korea Chemiluminescence Immunoassay Market Trends and Insights
- South Korea's advanced healthcare infrastructure, coupled with rising demand for rapid diagnostic solutions and automated laboratory systems, is driving market expansion.
- South Korea's strong pharmaceutical and diagnostics manufacturing base supports both domestic consumption and regional export opportunities in immunoassay technologies. The South Korea market is benefiting from increased prevalence of chronic diseases, aging demographics, and substantial investment in healthcare modernization.
- South Korea's regulatory environment and emphasis on precision medicine are accelerating adoption of chemiluminescence immunoassay platforms across clinical laboratories and hospital networks.
- South Korea's 8.0% compound annual growth rate outpaces the global average, reflecting the country's commitment to diagnostic innovation and healthcare quality standards through 2031..
Key Market Statistics
- CAGR (2026-2031) 8.0% CAGR
- Market Size, 2026 ~USD 155.7 Million
- Forecast, 2031 ~USD 228.8 Million
- Country South Korea
South Korea Chemiluminescence Immunoassay Market Overview
Market Valuation Growth :
South Korea's chemiluminescence immunoassay market is valued at USD 155.7 million in 2026, with a projected expansion to USD 228.8 million by 2031, representing an 8% CAGR—outpacing the global average of 7.2%.
Advanced Healthcare Infrastructure :
South Korea's sophisticated medical technology ecosystem and high healthcare spending per capita create an ideal environment for adoption of advanced diagnostic solutions and automated laboratory systems.
Rapid Diagnostic Demand :
Increasing prevalence of chronic diseases and infectious conditions in South Korea is driving demand for fast, accurate chemiluminescence immunoassay testing in clinical and hospital settings.
Automation & Laboratory Integration :
South Korean laboratories are increasingly investing in automated diagnostic platforms, positioning chemiluminescence immunoassay as a critical component of modernized laboratory workflows.
South Korea Chemiluminescence Immunoassay Market Dynamics
- The market benefits from strong government support for medical technology advancement, coupled with high adoption rates of automated laboratory systems among major hospitals and diagnostic centers.
- South Korea's aging population and rising incidence of lifestyle-related diseases are accelerating demand for efficient diagnostic solutions. Looking ahead to 2031, the market is expected to maintain its 8% CAGR trajectory, supported by continuous technological improvements, increasing healthcare expenditure, and expansion of point-of-care testing capabilities.
- Strategic partnerships between local manufacturers and international players, combined with regulatory support for advanced diagnostics, will further strengthen South Korea's position as a key market within the Asia Pacific region..
Related Ecosystem
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- South Korea's chemiluminescence immunoassay market is valued at USD 155.7 million in 2026 and is forecast to reach USD 228.8 million by 2031.
- South Korea's market growth rate of 8.0% CAGR exceeds the global average of 7.2%, driven by advanced healthcare infrastructure and diagnostic demand.
- South Korea's aging population and rising chronic disease prevalence are key drivers accelerating adoption of automated immunoassay platforms.
- South Korea's strong regulatory framework and precision medicine focus position the country as a regional leader in diagnostic technology innovation.
Chemiluminescence Immunoassay Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | ONCOLOGY (Application) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 7.2% from 2026 to 2031 |
| Largest Segment | CONSUMABLES (Product Type) |
| Market Size Base Year (Billions) | ~USD 11.58 (2026) |
| Revenue Forecast (Billions) | ~USD 16.39 (2031) |
| Segments Covered | Product Type, Technology, Sample Type, Application, End User |
South Korea Chemiluminescence Immunoassay Market Report Segmentation
5 segment dimensions are covered across the global market.
By Product Type
- Consumables
- Instruments
By Technology
- Chemiluminescence Enzyme Immunoassays (Cleia)
- Electrochemiluminescence Immunoassays (Ecli)
- Microparticle Chemiluminescence Immunoassays
By Sample Type
- Blood
- Other Sample Types
- Saliva
- Urine
By Application
- Allergy Diagnostics
- Autoimmune Disorders
- Blood Screening
- Bone & Mineral Disorders
- Cardiology
- Endocrinology
- Gastroenterology
- Infectious Diseases
- Metabolic Disorders
- Neurology
- Newborn Screening
- Oncology
- Other Applications
- Respiratory Diseases
- Therapeutic Drug Monitoring
- Toxicology
By End User
- Clinical Laboratories
- Hospitals
- Other End Users
- Pharmaceutical & Biotechnology Companies And Cros
Target Audience
- In Vitro Diagnostics Manufacturers : IVD companies seeking to expand or establish operations in South Korea need market sizing, competitive positioning, and growth trajectory data to inform product development and market entry strategies.
- Healthcare System Administrators : Hospital procurement teams and laboratory directors require market insights to evaluate chemiluminescence immunoassay solutions, benchmark pricing, and optimize diagnostic infrastructure investments.
- Medical Device Investors : Private equity and venture capital firms evaluating investment opportunities in South Korea's diagnostic sector need comprehensive market data, growth drivers, and risk assessments.
- Regulatory & Policy Bodies : South Korean health authorities and policy makers benefit from market analysis to inform healthcare technology regulations, reimbursement policies, and diagnostic standards development.
- Distributors & Channel Partners : Medical device distributors and laboratory equipment suppliers need country-specific market intelligence to identify growth opportunities, assess demand, and optimize distribution strategies in South Korea.
Key Companies in the South Korea Chemiluminescence Immunoassay Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ABBOTT | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and bioproduction solutions),Life Sciences (instruments, genomics, and research tools),Diagnostics (clinical instruments and consumables), |
| DIASORIN S.P.A. | Italy | Public Company | LIAISON XL / LIAISON XS immunodiagnostics,Molecular diagnostics (Simplexa, congenital CMV, LIAISON PLEX assays),xMAP technology platform and related IVD solutions, |
| QUIDELORTHO CORPORATION | United States | Public Company | Labs (clinical chemistry and immunoassay),Point of Care,Transfusion Medicine, |
| SYSMEX CORPORATION | Japan | Public Company | Hematology analyzers & reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems & reagents,Blood gas / electrolyte / urinalysis, |
| SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. | China | Public Company | Immunoassay analyzers and reagents,Biochemistry/Electrolyte systems and reagents,Integrated systems and lab automation, |
| TOSOH CORPORATION | Japan | Public Company | Basic chemicals and chlor-alkali (caustic soda, sodium bicarbonate, related),Vinyls, PVC chain, and petrochemicals (VCM, ethylene, propylene, aromatics),Advanced materials (battery materials, quartzware, silica glass, thin films, zeolites, zirconia, beads), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research Instruments and Consumables,Informatics and Software, |
| SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. | China | Public Company | Patient monitoring & life support (incl. ventilators, anesthesia, defibrillation, infusion),Ultrasound & medical imaging (incl. radiology, emergency ultrasound, endoscope camera systems),In-vitro diagnostics (CLIA, chemistry, hematology), |
ABBOTT
Abbott is a United States-based public company founded in 1888 with 115,000 employees, operating in the healthcare and pharmaceutical sectors.
SIEMENS HEALTHINEERS AG
Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and diagnostics.
DANAHER CORPORATION
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees operating across diversified industrial and life sciences sectors.
DIASORIN S.P.A.
DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees engaged in in vitro diagnostics and molecular diagnostics.
QUIDELORTHO CORPORATION
QuidelOrtho Corporation is a United States-based public company founded in 1979 with 6,500 employees specializing in diagnostic solutions.
SYSMEX CORPORATION
Sysmex Corporation is a Japanese public company founded in 1968 with 10,861 employees focused on in vitro diagnostics and hematology systems.
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
Shenzhen New Industries Biomedical Engineering Co., Ltd. is a Chinese public company founded in 1995 with 2,785 employees operating in the biomedical diagnostics sector.
TOSOH CORPORATION
Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees engaged in specialty chemicals and diagnostics.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a United States-based public company founded in 1952 with 7,450 employees providing life science research and clinical diagnostics products.
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is a Chinese public company founded in 1991 with 21,288 employees manufacturing medical devices and diagnostics equipment.
Reasons to Buy this Report
- Market-Specific Growth Projections : Access detailed forecasts showing South Korea's market expansion from USD 155.7M to USD 228.8M by 2031, with country-specific CAGR analysis exceeding global benchmarks.
- Competitive Landscape Intelligence : Identify key players, market share distribution, and strategic positioning of chemiluminescence immunoassay manufacturers operating within South Korea's healthcare sector.
- Regulatory & Reimbursement Insights : Understand South Korea's unique regulatory framework, healthcare reimbursement policies, and government initiatives supporting diagnostic technology adoption and market expansion.
- End-User Demand Analysis : Gain insights into hospital, diagnostic center, and laboratory preferences for chemiluminescence immunoassay systems, including adoption barriers and purchasing criteria specific to South Korea.
- Investment & Partnership Opportunities : Identify high-growth segments, emerging players, and strategic partnership opportunities within South Korea's rapidly expanding diagnostic immunoassay market.
Frequently asked questions
What is the current market size of chemiluminescence immunoassay in South Korea?
South Korea's chemiluminescence immunoassay market is valued at USD 155.7 million in 2026, with verified data from KS table sources.
What is the projected market size for South Korea by 2031?
South Korea's chemiluminescence immunoassay market is forecast to reach USD 228.8 million by 2031, representing significant growth over the five-year period.
What is South Korea's CAGR for the chemiluminescence immunoassay market?
South Korea's market is growing at a compound annual growth rate of 8.0% from 2026 to 2031, outpacing the global CAGR of 7.2%.
What factors are driving growth in South Korea's chemiluminescence immunoassay market?
South Korea's market growth is driven by advanced healthcare infrastructure, aging demographics, rising chronic disease prevalence, and increased investment in diagnostic automation and precision medicine.
How does South Korea's market performance compare to global trends?
South Korea's 8.0% CAGR exceeds the global average of 7.2%, reflecting the country's strong healthcare system, regulatory support, and commitment to diagnostic innovation.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the size of the CLIA market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.
Secondary Research
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and companies' SEC filings. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the CLIA market. It was also used to obtain important information on key players, market classification, and segmentation aligned with industry trends to the bottom-most level, and key developments from market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
Extensive primary research was conducted after secondary research provided information on the CLIA market. Several primary interviews were conducted with market experts from both the demand and supply sides across major countries of North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Primary data was collected through questionnaires, emails, and telephonic interviews. The primary sources from the supply side included various industry experts, such as Chief Executive Officers (CXOs), Vice Presidents (VPs), Directors from business development, marketing, and product development/innovation teams, as well as related key executives from manufacturers and distributors operating in the CLIA market.; and key opinion leaders.
Primary interviews were conducted to gather insights into market statistics, revenue from products and services, market breakdowns, market size estimates, market forecasting, and data triangulation. Primary research also helped in understanding the various trends in technology, applications, verticals, and regions. Stakeholders from the demand side, customers/end users who are using infection control products, were interviewed to understand the buyer’s perspective on the suppliers, products, and their current usage and the future outlook of their business, which will affect the overall market.
The following is a breakdown of the primary respondents:
Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
Note 2: Other primaries include sales managers, marketing managers, and product managers.
Note 3: Companies are classified into tiers based on their total revenue.
As of 2023: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, Tier 3=<USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The research methodology used to estimate the size of the CLIA market includes the following details.
The market sizing was conducted on a global basis.
Country-level Analysis: The size of the CLIA market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of products in the overall CLIA market was obtained from secondary data and validated by primary participants to arrive at the total CLIA market. Primary participants further validated the numbers.
Geographic market assessment (by region & country): The geographic assessment was done using the following approaches:
Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends
Approach 2: Geographic adoption trends for individual product segments by end user and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)
At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall CLIA market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.
Global Chemiluminescence Immunoassay Market : Top-Down and Bottom-Up Approach
Data Triangulation
The market was split into several segments and subsegments after determining the overall market size, using the market sizing processes. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for each market segment and subsegment. The data was triangulated by examining various factors and trends on both the demand and supply sides of the CLIA market.
Market Definition
Chemiluminescent immunoassay (CLIA) is an immunoassay technique in which the label, i.e., the indicator of the analytical reaction, is a luminescent molecule. CLIA is a variation of the standard enzyme immunoassay (EIA), a biochemical technique used in immunology. This variation technique can be used for medical diagnosis and in several other industries for various applications. In recent years, CLIA has attracted increasing attention across fields such as clinical diagnosis, life sciences, food safety, environmental monitoring, and pharmaceutical analysis, due to its high specificity, high sensitivity, broad applicability, simple instrumentation, and wide linear range.
Key Stakeholders
- CLIA manufacturers and distributors
- CLIA analyzers & consumables manufacturers
- Healthcare institutions (hospitals, medical schools, group practices, individual surgeons, and governing bodies)
- Healthcare institutions (hospitals and outpatient clinics)
- Distributors and suppliers
- Research institutes
- Health insurance payers
- World Health Organization (WHO)
- Organisation for Economic Co-operation and Development (OECD)
- National Institutes of Health (NIH)
- Centers for Disease Control and Prevention (CDC)
- Annual Reports/SEC Filings, Investor Presentations, and Press Releases of Key Players
- White Papers, Journals/Magazines, and News Articles
- Paid Databases, such as Factiva, D&B Hoovers, and Bloomberg Business
Report Objectives
- To define, describe, segment, and forecast the global CLIA market by product type, technology, sample type, application, end user, and region.
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall CLIA market.
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
- To forecast the size of the CLIA market in five main regions, along with their respective key countries, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players in the global CLIA market and comprehensively analyze their core competencies and market shares.
- To track and analyze competitive developments such as acquisitions, expansions, partnerships, agreements, and collaborations; and product launches and approvals.
- To benchmark players within the CLIA market using the "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.
Available customizations:
Based on the given market data, MarketsandMarkets offers customizations tailored to the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the Rest of Asia Pacific CLIA market into Thailand, Indonesia, Philippines, Vietnam, Hong Kong, and other countries
- Further breakdown of the Rest of Europe CLIA market into Belgium, Russia, the Netherlands, Switzerland, and other countries.
- Further breakdown of the Rest of Latin America CLIA market into Argentina, Peru, and other countries.
Get the Full Chemiluminescence Immunoassay Market Report
Full forecast, segment splits, and company analysis for all Chemiluminescence Immunoassay Market.
- US Chemiluminescence Immunoassay Market
- Canada Chemiluminescence Immunoassay Market
- Germany Chemiluminescence Immunoassay Market
- France Chemiluminescence Immunoassay Market
- UK Chemiluminescence Immunoassay Market
- Italy Chemiluminescence Immunoassay Market
- Spain Chemiluminescence Immunoassay Market
- China Chemiluminescence Immunoassay Market
- Japan Chemiluminescence Immunoassay Market
- India Chemiluminescence Immunoassay Market
- Australia Chemiluminescence Immunoassay Market
- Brazil Chemiluminescence Immunoassay Market
- Mexico Chemiluminescence Immunoassay Market
- Rest Of Europe Chemiluminescence Immunoassay Market
- Rest Of Asia Pacific Chemiluminescence Immunoassay Market
- Rest Of Latin America Chemiluminescence Immunoassay Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report